Hospital Antibiotic Reviews

Why did COVID-19 make antibiotic reassessment so important?

Almost 80% of patients hospitalized with COVID-19 received an antibiotic between March and October 2020, according to CDC. Its pandemic review also describes staffing shortages, longer hospital stays, and greater use of invasive devices that complicated infection prevention. These historical findings explain the need for better prescribing oversight; they do not establish that every antibiotic prescription was unnecessary. The CDC webpage is dated February 2025 and summarizes earlier evidence. [CDC pandemic review](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).

The treatment question is whether a patient also has a bacterial infection. WHO's June 2025 clinical management guideline recommends against starting antibiotics empirically in non-severe COVID-19 when suspicion of concurrent bacterial infection is low. For severe COVID-19 with similarly low suspicion, it makes a conditional recommendation against empirical antibiotics. Empirical treatment means prescribing before the suspected infection is confirmed. These recommendations depend on clinical assessment, and suspicion of bacterial infection can change as the illness evolves. [WHO clinical management guideline](https://www.who.int/publications/i/item/B09467).

What should doctors check during an antibiotic review?

An antibiotic review connects the initial prescription with information that becomes available later. Culture results and other diagnostic findings may support continuing treatment, choosing a more targeted drug, or stopping antibiotics when a bacterial infection is no longer considered likely. CDC also identifies opportunities to switch suitable patients from intravenous treatment to oral medication and to adjust doses when necessary. [CDC hospital stewardship guidance](https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-h.pdf).

A review at 48–72 hours is one approach, but CDC says the optimal timing has not been established. It cites a trial in which these reviews improved antibiotic selection without reducing overall use. Reviews led by treating clinicians therefore supplement specialist prescribing feedback. The practical implication is that a reminder alone may be insufficient: someone must interpret the findings and act on them. [CDC guidance on antibiotic reassessment](https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-h.pdf).

Can prescribing programs safely shorten antibiotic treatment?

A 2017 Cochrane review included 221 studies of interventions to improve hospital antibiotic prescribing. Across 14 randomized trials involving 3,318 participants, treatment duration fell by an average of 1.95 days compared with usual care. Separate mortality analyses supported the conclusion that reducing antibiotic use through these interventions probably did not increase deaths. The review covered varied prescribing strategies and searched evidence through January 2015; its findings do not establish that every infection should receive a shorter course or that a single reassessment produces the same benefit. [Cochrane systematic review](https://doi.org/10.1002/14651858.CD003543.pub4).

Avoiding unnecessary treatment also limits exposure to antibiotic adverse effects. CDC lists diarrhea, nausea, and rash among possible reactions, alongside serious complications such as Clostridioides difficile infection and severe allergic reactions. For patients, the useful questions are what infection the medicine is treating, when the prescription will be reviewed, and how long treatment is planned. Take antibiotics as prescribed and contact the treating clinician about changes or side effects. [CDC antibiotic guidance](https://www.cdc.gov/antibiotic-use/about/index.html).